Tag Archive | "Mitsubishi"

Top 50 Pharma (top pharmaceutical companies)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,


The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Mitsubishi Tanabe: M&A activity 2005-2013

Tags: , ,


A recently formed company, Mitsubishi Tanabe, has already announced 3 M&A deals since 2005. Read the full story

Mitsubishi Tanabe: Partnering activity 2005-2013

Tags: , ,


Mitsubishi Tanabe, a big pharma company based in Japan, announced over 20 partnering / licensing deals since 2005. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology and central nervous system diseases. Read the full story

Partnering Agreements with Mitsubishi Tanabe

Tags: , , , , , , ,


This report provides all the information you require to better understand Mitsubishi Tanabe and its partnering interests and activities over the past seven years. Read the full story

Vertex Pharmaceuticals receives $105M in amended Telaprevir deal with Mitsubishi Tanabe

Tags: , ,


Under the terms of the amended agreement, Vertex will receive $105 million following signing, and will be eligible to receive further milestones upon approval and commercialization in Japan. Read the full story

Odyssey Thera in collaboration with Mitsubishi Tanabe Pharma for analysis of drug candidates

Tags: ,


Odyssey Thera will apply its patented Protein-fragment Complementation Assay (PCA), proprietary High Context Screening infrastructure, unique institutional knowledge, and state-of-the-art data analysis strategies in the collaboration to yield valuable insights related to drug selectivity, safety, and mechanisms of action. Financial terms of the collaboration were not disclosed.

deCODE biostructures and Mitsubishi Tanabe initiate fragments of Life screening for fragment based lead discovery

Tags: ,


Successful completion of a research collaboration with the delivery of structure milestones to Mitsubishi Tanabe Pharma Corporation against an undisclosed novel target. Read the full story

Affectis and Mitsubishi Tanabe Pharma in drug discovery collaboration

Tags: ,


Affectis will receive research fees from MTPC as well as development milestones. Read the full story

EnVivo Pharmaceuticals and Mitsubishi Tanabe Pharma enter license agreement on EVP-6124 in Japan, Korea, Taiwan and other Asian countries

Tags: ,


MTPC has obtained exclusive rights to develop and commercialize EnVivo's alpha-7 nicotinic acetylcholine receptor agonists such as EVP-6124 in Japan, Korea, Taiwan, Indonesia and several other Asian markets. MTPC plans to initiate Phase I clinical trials within 2010. Read the full story